- Home
- IMNN vs CRIS Comparison
IMNN vs CRIS Comparison
Compare IMNN & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- CRIS
- Stock Information
- Founded
- IMNN 1982
- CRIS 2000
- Country
- IMNN United States
- CRIS United States
- Employees
- IMNN N/A
- CRIS N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMNN Health Care
- CRIS Health Care
- Exchange
- IMNN Nasdaq
- CRIS Nasdaq
- Market Cap
- IMNN 12.9M
- CRIS 14.6M
- IPO Year
- IMNN 1985
- CRIS 2000
- Fundamental
- Price
- IMNN $3.77
- CRIS $1.14
- Analyst Decision
- IMNN Buy
- CRIS Strong Buy
- Analyst Count
- IMNN 2
- CRIS 2
- Target Price
- IMNN $182.61
- CRIS $16.50
- AVG Volume (30 Days)
- IMNN 56.4K
- CRIS 90.8K
- Earning Date
- IMNN 11-13-2025
- CRIS 11-06-2025
- Dividend Yield
- IMNN N/A
- CRIS N/A
- EPS Growth
- IMNN N/A
- CRIS N/A
- EPS
- IMNN N/A
- CRIS N/A
- Revenue
- IMNN N/A
- CRIS $11,650,000.00
- Revenue This Year
- IMNN N/A
- CRIS $2.72
- Revenue Next Year
- IMNN N/A
- CRIS $8.27
- P/E Ratio
- IMNN N/A
- CRIS N/A
- Revenue Growth
- IMNN N/A
- CRIS 13.56
- 52 Week Low
- IMNN $3.56
- CRIS $1.02
- 52 Week High
- IMNN $41.22
- CRIS $4.70
- Technical
- Relative Strength Index (RSI)
- IMNN 35.44
- CRIS 35.27
- Support Level
- IMNN $3.56
- CRIS $1.06
- Resistance Level
- IMNN $4.38
- CRIS $1.35
- Average True Range (ATR)
- IMNN 0.30
- CRIS 0.12
- MACD
- IMNN 0.00
- CRIS -0.01
- Stochastic Oscillator
- IMNN 21.95
- CRIS 16.26
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.